{"id":70550,"date":"2023-02-17T08:14:23","date_gmt":"2023-02-17T07:14:23","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=70550"},"modified":"2023-02-16T19:36:28","modified_gmt":"2023-02-16T18:36:28","slug":"francia-roche-e-novartis-assolte-non-dovranno-pagare-444-milioni-di-euro","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/francia-roche-e-novartis-assolte-non-dovranno-pagare-444-milioni-di-euro\/","title":{"rendered":"FRANCE. Roche and Novartis acquitted, they will not have to pay 444 million euros"},"content":{"rendered":"
<\/div>\n

The maxi-fines dating back to last 2020 and imposed in France on the two pharmaceutical giants for abuse of a dominant position have been canceled<\/span><\/p>\n

\"\"PARIS \u2013 The maxi-fines imposed on Roche and Novartis in France in September 2020 have been canceled: the Paris appeals court annulled the fines for a total of 444 million euros (439 million francs at current exchange rates) decided by the French authority competition (AFC) for abuse of dominant position.<\/p>\n

The detail \u2013 Roche should have paid out 385 million euros, Novartis 60 million. The companies had been punished for trying to preserve sales of the drug Lucentis (against age-related macular degeneration, AMD or AMD) at the expense of the 30 times cheaper Avastin.<\/p>\n

Both preparations were developed by the American biotech company Genentech, which was taken over by Roche in 2009. However, Lucentis is marketed by Novartis outside the United States. As known, Roche and Novartis had ended up in the crosshairs of the authorities also in Italy for the two ophthalmic drugs in question.<\/p>\n

According to the AFC, the pharmaceutical giants in the Rhineland had colluded to discredit the use of Avastin in ophthalmology, both among healthcare professionals and vis-\u00e0-vis the French government. The regulator charged the companies with illegal practices, from 2008 to 2013 for Roche and from 2011 to 2013 for Genentech.<\/p>\n

The ruling \u2013 But in a ruling released today, the Paris court of appeals held that starting in 2011, with the entry into force of the new legislation, Avastin should be considered off the market for the treatment of AMD. The two preparations in question could not therefore validly compete with each other. Furthermore, the communications of the companies were measured in terms of tone, not disparaging, nor alarmist or even misleading.<\/p>\n

Ticino TIO20 \u2013 16 February 2023<\/a><\/p>\n

Related news:\u00a0The fine record inflicted on Novartis and Roche is cancelled<\/a><\/p>\n

Novartis exits Roche, a 19 billion operation<\/a><\/p>\n

Lucentis Avastin case: Novartis acquitted by the Court of Rome<\/a><\/p>\n

Cassation. Final fines to Hoffmann-La Roche and Novartis for cartel on Lucentis<\/a><\/p>\n

\n
\n
\n
\n

Cassation. Civil Judgment Section U No. 26920 Year 2021<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Cancellate le maxi-multe risalenti allo scorso 2020 e inflitte in Francia ai due colossi della farmaceutica per abuso di posizione dominante PARIGI – Cancellate le maxi-multe inflitte nel settembre 2020 in Francia a Roche e Novartis: la corte d’appello di Parigi ha annullato le sanzioni per complessivi 444 milioni di euro (439 milioni di franchi …<\/p>","protected":false},"author":4,"featured_media":70555,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[41,33,22],"class_list":["post-70550","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-leggisentenze","tag-roche","tag-truffa-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=70550"}],"version-history":[{"count":10,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70550\/revisions"}],"predecessor-version":[{"id":70561,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/70550\/revisions\/70561"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/70555"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=70550"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=70550"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=70550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}